Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04661267 · ClinicalTrials.gov registry record · NA
Randomized Trial of Regenexx Stem Cell Support Formula
A NA study, sponsored by Regenexx.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT04661267: Completed NA study, sponsored by Regenexx.
NCT04661267 is a NA study that has completed, run by Regenexx. The registered enrollment target is 80 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04661267, a NA study, has completed, sponsored by Regenexx.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
Regenexx, LLC developed a nutritional supplement formula containing many components related to supporting healthy joints This oral, liquid supplement is intended to help improve joint and cartilage health while also increasing their joint function. The goal of this study is to measure changes in joint health and function for patients with knee OA taking this supplement for 2 months.
Primary Outcome
The difference between groups of the within patient mean change from baseline to 2 months.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Stem Cell Support Formula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-02-03 |
| Est. Completion | 2022-10-31 |
| Phase | NA |
What the finished NCT04661267 record still lists
NCT04661267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04661267 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04661267 about?
NCT04661267 is a clinical study titled "Randomized Trial of Regenexx Stem Cell Support Formula". Regenexx, LLC developed a nutritional supplement formula containing many components related to supporting healthy joints This oral, liquid supplement is intended to help improve joint and cartilage health while also increasing their joint function. The goal of this study is to measure changes in joi...
What is the current status of trial NCT04661267?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2021-02-03. Estimated completion is 2022-10-31.
What interventions are being tested in trial NCT04661267?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Stem Cell Support Formula (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04661267?
This trial is sponsored by Regenexx, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04661267's enrollment target sits among peer trials
80 994th of 2000 higher than 941 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI